Drug Safety Alert: Indian Pharmacopoeia Commission Flags ADR Linked To Metronidazole

Written By :  Susmita Roy
Medically Reviewed By :  Dr. Kamal Kant Kohli
Published On 2024-09-04 08:30 GMT   |   Update On 2024-09-04 08:30 GMT
Advertisement

New Delhi: The Indian Pharmacopoeia Commission (IPC), through its recently issued drug safety alert for the month of August, has revealed that the popular antibiotic Metronidazole is linked with adverse drug reactions (ADRs) named Fixed Drug Eruption (FDE).

In connection with the above, the Indian Pharmacopoeia Commission (IPC) has cautioned healthcare professionals to diligently monitor the potential occurrence of adverse drug reactions (ADRs) when administering metronidazole.

Advertisement

This came after a preliminary analysis of adverse drug reactions (ADRs) from the Pharmacovigilance Programme of India (PvPI) database.

Metronidazole is a commonly used antibiotic, belonging to the nitroimidazole class of antibiotics. It is frequently used to treat gastrointestinal infections as well as trichomoniasis giardiasis, and amebiasis, which are parasitic infections.

After administration, metronidazole enters cells by passive diffusion. Following this, ferredoxin or flavodoxin reduce its nitro group to nitro radicals. The redox potential of the electron transport portions of anaerobic or microaerophilic microorganisms renders metronidazole selective to these organisms, which cause nitro group reduction, leading to the production of toxic metabolites. These include N-(2-hydroxyethyl) oxamic acid and acetamide, which may damage the DNA of replicating organisms.

The alert noted that metronidazole is indicated for the treatment of amoebiasis, urogenital trichomoniasis and giardiasis.

Following the preliminary analysis of adverse drug reactions (ADRs) from the PvPI database, it is reported that metronidazole can lead to Fixed Drug Eruption (FDE).

A fixed-drug eruption (FDE) is a unique cutaneous adverse drug effect in the form of recurrent lesions at the same site after re-exposure to the offending agent.

Now, as per the issued drug safety alert, the following suspected drug is associated with the ADR, as given below:

Sr. No

Suspected Drug

Indication

Adverse Drug Reaction

1

Metronidazole

For the treatment of Amoebiasis, urogenital trichomoniasis & giardiasis

Fixed Drug Eruption (FDE)

In light of the above, the Indian Pharmacopoeia Commission, Ministry of Health & Family Welfare, has advised healthcare professionals, patients, and consumers to closely monitor the possibility of the above ADRs associated with the use of the above-suspected drugs.

Further, the safety alert added, "If such reaction is encountered, please report to the NCC-PvPI, IPC by filling out Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in), through Android Mobile App "ADR PvPI App" and PvPIHelpline No. 1800-180-3024 (Toll-Free).

To view the official notice, click the link below:

Tags:    

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News